PMID- 20348036
OWN - NLM
STAT- MEDLINE
DCOM- 20100903
LR  - 20181201
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 10
IP  - 6
DP  - 2010 Jun
TI  - Effects of ropivacaine on adhesion molecule CD11b expression and function in 
      human neutrophils.
PG  - 662-7
LID - 10.1016/j.intimp.2010.03.009 [doi]
AB  - Local anesthetics possess a wide range of anti-inflammatory properties through 
      their effects on neutrophils. However, limited information is available on the 
      effects of ropivacaine (a new local anesthetic) on neutrophil function. The aim 
      of this study was to investigate anti-inflammatory properties of ropivacaine with 
      regard to its effects on the expression and function of CD11b in human 
      neutrophils. CD11b expression was examined by flow cytometry and its function was 
      determined by measuring adhesion of neutrophils to human umbilical vein 
      endothelial cells (HUVECs). Ropivacaine inhibited CD11b expression in 
      formyl-methionyl-leucyl-phenylalanine (fMLP)-activated neutrophils in a 
      concentration-dependent manner, but not in a time-dependent manner. The 
      inhibitory potency of ropivacaine was similar to that of bupivacaine and 
      levobupivacaine, but was more potent than that of lidocaine. The up-regulation of 
      CD11b induced by platelet-activating factor (PAF) priming was also inhibited by 
      ropivacaine. fMLP increased adhesion of neutrophils to HUVECs, which was 
      inhibited by ropivacaine. In addition, ropivacaine more potently inhibited the 
      fMLP-induced CD11b expression in the presence of ethylene 
      glycol-bis(2-aminoethylether)-N,N,N ,N -tetraacetic acid (EGTA), a chelator of 
      extracellular Ca(2+). However, ropivacaine showed no effect on the fMLP-induced 
      CD11b expression in the presence of butan-1-ol, a blocker of phospholipase D 
      (PLD) pathway, which completely inhibited the fMLP-induced CD11b expression in 
      neutrophils. Our results suggest that ropivacaine exerts anti-inflammatory 
      activity, and this appears to be mediated through inhibiting the expression and 
      function of adhesion molecule CD11b in neutrophils.
CI  - Copyright 2010 Elsevier B.V. All rights reserved.
FAU - Zhu, Xuqin
AU  - Zhu X
AD  - Department of Anesthesiology, Fudan University Cancer Hospital, No. 270 Dong-an 
      Road, Shanghai, PR China.
FAU - Tan, Zhiming
AU  - Tan Z
FAU - Chen, Jiawei
AU  - Chen J
FAU - Zhu, Minmin
AU  - Zhu M
FAU - Xu, Yajun
AU  - Xu Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100327
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Amides)
RN  - 0 (Anesthetics, Local)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (CD11 Antigens)
RN  - 0 (Platelet Activating Factor)
RN  - 526U7A2651 (Egtazic Acid)
RN  - 59880-97-6 (N-Formylmethionine Leucyl-Phenylalanine)
RN  - 7IO5LYA57N (Ropivacaine)
RN  - 8PJ61P6TS3 (1-Butanol)
RN  - EC 3.1.4.4 (Phospholipase D)
SB  - IM
MH  - 1-Butanol/immunology
MH  - Amides/*pharmacology
MH  - Anesthetics, Local/*pharmacology
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - CD11 Antigens/*biosynthesis
MH  - Cell Adhesion/drug effects/immunology
MH  - Egtazic Acid/immunology
MH  - Endothelial Cells/drug effects/immunology
MH  - Humans
MH  - N-Formylmethionine Leucyl-Phenylalanine/immunology
MH  - Neutrophils/*drug effects/immunology
MH  - Phospholipase D/immunology
MH  - Platelet Activating Factor/immunology
MH  - Ropivacaine
MH  - Umbilical Veins/drug effects/immunology
EDAT- 2010/03/30 06:00
MHDA- 2010/09/04 06:00
CRDT- 2010/03/30 06:00
PHST- 2009/11/25 00:00 [received]
PHST- 2010/02/09 00:00 [revised]
PHST- 2010/03/12 00:00 [accepted]
PHST- 2010/03/30 06:00 [entrez]
PHST- 2010/03/30 06:00 [pubmed]
PHST- 2010/09/04 06:00 [medline]
AID - S1567-5769(10)00093-7 [pii]
AID - 10.1016/j.intimp.2010.03.009 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2010 Jun;10(6):662-7. doi: 10.1016/j.intimp.2010.03.009. 
      Epub 2010 Mar 27.